Newly created position to lead efforts focused on continued growth and salesSOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Legend Biotech (LEGN – Research ...

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader ...

Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese ...

Legend Biotech has reduced Genscript Biotech's control, lowering its voting power below 50%, amid growing US scrutiny of ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Legend Biotech in a research ...

On Wednesday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $43.95 which represents a decrease of $-1.08 or -2.40% from the prior close of $45.03. The stock opened at $44.71 and ...

On Monday, Legend Biotech Corp (LEGN) stock saw a modest uptick, ending the day at $45.3 which represents a slight increase of $0.56 or 1.25% from the prior close of $44.74. The stock opened at $44.96 ...

On Friday, TD Cowen maintained a positive outlook on shares of Legend Biotech Corp. (NASDAQ:LEGN), reasserting a Buy rating and a $67.00 price target for the company's stock. The firm's stance ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...